No 1 Date of announcement 2025/12/15 Time of announcement 18:06:16 Subject The Company announces the information about the investor conference of Q4, 2025. Date of events 2025/12/23 To which item it meets paragraph 12 Date of institutional investor conference:2025/12/23 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference: Online investor conference Outline of...Read More
No 1 Date of announcement 2025/09/18 Time of announcement 17:02:34 Subject The Company announces the information about the investor conference of Q3, 2025. Date of events 2025/09/18 To which item it meets paragraph 12 Date of institutional investor conference:2025/09/25 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference: Online investor conference Outline of...Read More
Published: 2024-12-25 2024-12-25 On the 24th, SINEW PHARMA announced that its innovative pain relief drug, SNP-810, a high-liver-safety acetaminophen, has successfully completed toxicology testing on large animals (dogs) conducted by the globally renowned Charles River Laboratories. The results confirmed that the drug maintains excellent safety even at extremely high doses (equivalent to 38 tablets of...Read More
Published: 2024-07-08 Diamond Biofund (TWSE:6901) announced today the signing of a Memorandum of Understanding (MoU) with French biotech venture fund – AdBio Partners (www.adbio.partners). Both parties announced the establishment of a cross-border investment cooperation to facilitate flagship investments in the biotech and medical sectors. AdBio Partners (formerly Advent France Biotechnology) was established in Paris in...Read More
Published: 2024-06-19 No 1 Date of announcement 2024/06/19 Time of announcement 15:25:07 Subject The Company announces the information about the investor conference of Q2, 2024. Date of events 2024/06/19 To which item it meets paragraph 12 Date of institutional investor conference:2024/06/26 Time of institutional investor conference:15:00 (GMT+8) Location of institutional investor conference:Online investor conference...Read More
May 2024 StemCyte CEO Tong-Young Lee PhDTong-Young Lee, PhD, is a modest man who will repeatedly tell you that he “was lucky”, when it is clear that much of his success is the result of brilliance and hard work. Tong-Young Lee grew up in Taiwan and earned a PhD in pathology from Taiwan National...Read More
Published: 2024-05-23 NEWS PROVIDED BY StemCyte May 23, 2024, 11:47 ET BALDWIN PARK, Calif., May 23, 2024 /PRNewswire/ — StemCyte, a leader in cord blood-based regenerative therapeutics in Southern California, is excited to announce the renewal of its partnership with the California State Umbilical Cord Blood Collection Program (CA-UCBCP). In collaboration with UC Davis Health,...Read More
Published: 2023-11-10 Cross-Border Collaboration Facilitates Flagship Biotech Investments Joint News Release Date: November 5th, 2023 Leading Taiwanese and Japanese biotech venture capitals ally. Diamond Biofund from Taiwan and DCI Partners Co., Ltd. (wholly owned by Daiwa Securities Group, referred to as DCI Partners) from Japan jointly announced that the two parties have established a cross-border...Read More
Published: 2023-11-09 Diamond Biofund invests in full speed after its listing in Taiwian Stock Exchange. Following investing in Syncell, Diamond Biofund has announced on Nov. 8th, 2023 a significant addition of US$6.35 million investment in StemCyte to support its novel cell therapy entering into the global market and its successful capital raise of over US$25...Read More
Published: 2023-10-31 Taiwan’s first Taiwan Stock Exchange (TWSE)-listed venture capital firm, Diamond Biofund, has proudly announced a substantial investment of US$4 million in SYNCELL Inc. This investment is intended to facilitate the pilot production of cutting-edge Spatial Biology instruments in Taiwan, preparing for global market entry. Founded by Dr. Chung-Chi Liao, SYNCELL Inc., a spin-off...Read More
